Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients
OFF Time Was Reduced With Longer-Acting Levodopa Product
The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose.
You may also be interested in...
Amneal says it is taking initiatives to improve its generics margins by improving its manufacturing and supply chain, after its generics segment was sales drop by 11% in the first quarter. Amneal is aiming to deliver six to seven high-value products annually, while the company is also looking to launch three biosimilars in the next couple of years.
The FDA on 8 January finally gave its blessing to Impax Pharmaceuticals to market its Parkinson's disease drug Rytary, an extended-release oral capsule formulation of carbidopa-levodopa.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.